Jyong Biotech closed at $1.65 on Nov 5, down 5.17%, 96.0% below its 52-week closing high. Volume of 30.4K shares was 0.65× its 20-day average (below normal).
Split-adjusted performance: -19.9% over one month, -19.5% over six months, -96.0% over one year.
Short interest was 213.3K shares at the Oct 15 settlement, down 4.0% from the prior report (0.7% of float, 5.3 days to cover).
Jyong Biotech Ltd is research and develop new drugs for today's great unmet medical needs and planned to manufacture and sell new drugs after receiving regulatory approval. It is a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia.
What is MENS's market cap?
$122.49M, based on the Nov 5 close of $1.65.
Does Jyong Biotech pay a dividend?
No regular cash dividend has been paid in the last year.
How much of MENS is sold short?
213.3K shares, 0.7% of float, as of Oct 15, 2026.
About Jyong Biotech
Jyong Biotech Ltd is research and develop new drugs for today's great unmet medical needs and planned to manufacture and sell new drugs after receiving regulatory approval. It is a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. The Group operates and manages its business as a single segment in the research and development of novel therapeutics targeting unmet needs. The company's product pipeline includes MCS-2, PCP, IC.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology